Defining the Role of CD4+CD25+ Immunoregulatory T-Cells in the Treatment of Patients With Advanced Ovarian Cancer Who Receive Dendritic Cell Based Vaccine Therapies.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Denileukin diftitox (Primary) ; Ovarian cancer vaccine
- Indications Ovarian cancer
- Focus Pharmacodynamics
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 29 Oct 2012 Planned end date changed from 1 May 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 08 Mar 2011 Planned end date changed from 1 Jan 2010 to 1 May 2012 as reported by ClinicalTrials.gov.